Tarsus Pharmaceuticals, Inc.(TARS)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

TARS Tarsus Pharmaceuticals, Inc.

休市中 08-14 16:00:00 EDT

69.20

+0.32

+0.46%

盘后69.20

+0.000.00%

19:34 EDT

最高69.70	最低67.61	成交量44.83万
今开68.82	昨收68.88	日振幅3.03%
总市值30.37亿	流通市值22.38亿	总股本4,388万
成交额3,094万	换手率1.39%	流通股本3,235万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"TARS","market":"US","secType":"STK","nameCN":"Tarsus Pharmaceuticals, Inc.","latestPrice":69.2,"timestamp":1786737600000,"preClose":68.88,"halted":0,"volume":448260,"hourTrading":{"tag":"盘后","latestPrice":69.2,"preClose":69.2,"latestTime":"19:34 EDT","volume":15460,"amount":1069832,"timestamp":1786750443281,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.0046457607433218265,"floatShares":32346900,"shares":43882996,"eps":-1.082408,"marketStatus":"休市中","change":0.32,"latestTime":"08-14 16:00:00 EDT","open":68.82,"high":69.7,"low":67.61,"amount":30936143.9184,"amplitude":0.030343,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.082408,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1786953600000},"marketStatusCode":7,"adr":0,"listingDate":1602820800000,"exchange":"NASDAQ","adjPreClose":68.88,"preHourTrading":{"tag":"盘前","latestPrice":69.78,"preClose":68.88,"latestTime":"04:00 EDT","volume":3,"amount":209.34,"timestamp":1786694411038,"change":0.9,"changeRate":0.013066,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":69.2,"preClose":69.2,"latestTime":"19:34 EDT","volume":15460,"amount":1069832,"timestamp":1786750443281,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.5187128201425262,"impliedVol":0.4413,"impliedVolPercentile":0.2351},"requestUrl":"/m/hq/s/TARS","defaultTab":"news","newsList":[{"id":"1133083260","title":"Tarsus Pharmaceuticals 有望获得高达3.5亿美元里程碑付款，条件为监管批准及首次销售","url":"https://stock-news.laohu8.com/highlight/detail?id=1133083260","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1133083260?lang=zh_cn&edition=full","pubTime":"2026-08-06 19:02","pubTimestamp":1786014139,"startTime":"0","endTime":"0","summary":"Tarsus Pharmaceuticals, Inc. 正迎来一项重大财务激励。根据披露，该公司在监管机构批准其产品并实现首次销售后，将可能收取高达3.5亿美元的里程碑付款。这一潜在收益凸显了市场对其在研疗法商业前景的积极预期，也将为公司的现金储备注入强劲动力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TARS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127897452","title":"新闻稿：Tarsus Pharmaceuticals 宣布高管领导层变动，公司迈入增长新阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=1127897452","media":"投资观察","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1127897452?lang=zh_cn&edition=full","pubTime":"2026-07-14 04:13","pubTimestamp":1783973630,"startTime":"0","endTime":"0","summary":"加州尔湾，2026年7月13日——Tarsus Pharmaceuticals, Inc.  今日宣布，首席商务官Aziz Mottiwala将离职，以出任一家上市医疗器械公司的首席执行官，寻求新的职业发展。此次领导层变动正值Tarsus进入新的增长阶段。本新闻稿中包含的任何前瞻性陈述均基于Tarsus管理团队当前的预期，且仅代表截至发布之日的情况。Tarsus明确声明，除非法律要求，否则没有义务因新信息、未来事件或其他原因而更新任何前瞻性陈述。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TARS","BK4022","R","BK4232"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170572679","title":"Tarsus制药公司交易预付款总额达7500万美元：现金与股票各占3750万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1170572679","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1170572679?lang=zh_cn&edition=full","pubTime":"2026-07-09 04:11","pubTimestamp":1783541487,"startTime":"0","endTime":"0","summary":"Tarsus Pharmaceuticals, Inc.达成一项交易，其预付款总额确定为7500万美元。这笔款项结构均衡，其中3750万美元将以现金形式支付，另外3750万美元则通过公司股票支付。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TARS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114892597","title":"Tarsus通过收购Irenix Medical及后期资产Irx-101推进眼科护理领导力战略","url":"https://stock-news.laohu8.com/highlight/detail?id=1114892597","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1114892597?lang=zh_cn&edition=full","pubTime":"2026-07-09 04:06","pubTimestamp":1783541203,"startTime":"0","endTime":"0","summary":"Tarsus Pharmaceuticals, Inc.正通过收购Irenix Medical及其处于后期开发阶段的资产Irx-101，积极推动其眼科护理领域的领导力战略。此举旨在强化公司在专业眼科治疗市场的布局，并获取具有潜力的创新疗法。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TARS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117934257","title":"做空机构Culper Research宣布做空Tarsus Pharmaceuticals","url":"https://stock-news.laohu8.com/highlight/detail?id=1117934257","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1117934257?lang=zh_cn&edition=full","pubTime":"2026-07-07 16:49","pubTimestamp":1783414199,"startTime":"0","endTime":"0","summary":"做空机构Culper Research于7月1日宣布，其已建立对Tarsus Pharmaceuticals, Inc.的空头头寸。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TARS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134028917","title":"Tarsus与约翰·塞纳携手合作，提升公众对蠕形螨睑缘炎的认知，该常见眼睑疾病影响约2500万美国人","url":"https://stock-news.laohu8.com/highlight/detail?id=1134028917","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1134028917?lang=zh_cn&edition=full","pubTime":"2026-05-14 20:33","pubTimestamp":1778762004,"startTime":"0","endTime":"0","summary":"Tarsus Pharmaceuticals, Inc. 与知名人士约翰·塞纳建立合作伙伴关系，共同致力于提升公众对蠕形螨睑缘炎的认识。这是一种普遍的眼睑疾病，在美国大约有2500万人受其影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TARS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173385123","title":"Tarsus Pharmaceuticals重申2026年Xdemvy净产品销售指导目标为6.7-7亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1173385123","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1173385123?lang=zh_cn&edition=full","pubTime":"2026-05-07 04:08","pubTimestamp":1778098089,"startTime":"0","endTime":"0","summary":"Tarsus Pharmaceuticals, Inc. 再次确认了2026财年的业绩指引，预计其核心产品Xdemvy的净销售额将达到6.7亿至7亿美元区间。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TARS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100601310","title":"Tarsus启动Calliope二期临床研究：首例受试者接受TP-05（洛替拉纳）给药，探索口服片剂预防莱姆病潜力","url":"https://stock-news.laohu8.com/highlight/detail?id=1100601310","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1100601310?lang=zh_cn&edition=full","pubTime":"2026-03-31 20:33","pubTimestamp":1774960394,"startTime":"0","endTime":"0","summary":"生物制药公司Tarsus Pharmaceuticals, Inc.宣布，其创新口服片剂TP-05（洛替拉纳）用于潜在预防莱姆病的二期临床试验\"Calliope\"已完成首例受试者给药。该研究旨在评估这款基于lotilaner成分的试验性药物在疾病预防领域的应用前景。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TARS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183553864","title":"Tarsus Pharmaceuticals, Inc. - 莱姆病疫苗患者招募将于2026年蜱虫季节完成，顶线结果预计2027年上半年公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1183553864","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1183553864?lang=zh_cn&edition=full","pubTime":"2026-03-31 20:33","pubTimestamp":1774960384,"startTime":"0","endTime":"0","summary":"Tarsus Pharmaceuticals, Inc. 近日披露了其针对莱姆病的主要在研疫苗项目的最新进展。根据公司规划，该候选疫苗的患者招募工作预计将在2026年蜱虫活跃季节全面完成。紧随招募完成之后，研究团队将进入密集的数据收集与统计分析阶段。公司明确表示，该项目的重要顶线结果预计将于2027年上半年对外公布。若数据积极，将为后续向监管机构提交申请奠定坚实基础，并有望填补当前莱姆病预防领域存在的重大未满足医疗需求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TARS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106157557","title":"Tarsus制药公司TP-03在大中华区有望获得额外里程碑付款及分级特许权使用费","url":"https://stock-news.laohu8.com/highlight/detail?id=1106157557","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1106157557?lang=zh_cn&edition=full","pubTime":"2026-03-23 20:35","pubTimestamp":1774269325,"startTime":"0","endTime":"0","summary":"Tarsus Pharmaceuticals, Inc.（以下简称Tarsus）宣布，其核心产品TP-03在大中华区达成特定开发与商业化目标后，将有资格获得额外里程碑款项。根据协议条款，Tarsus还可依据TP-03在该区域的销售额享受分级特许权使用费。\n这一安排进一步巩固了Tarsus在大中华区的战略布局，为TP-03的未来市场表现提供了额外的财务激励。TP-03作为一种创新疗法，其在大中华区的进展备受市场关注。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TARS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1140604175","title":"TP-03（洛替拉纳滴眼液）0.25%在华获批治疗蠕形螨睑缘炎，触发向Tarsus支付1500万美元里程碑款项","url":"https://stock-news.laohu8.com/highlight/detail?id=1140604175","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1140604175?lang=zh_cn&edition=full","pubTime":"2026-03-23 20:31","pubTimestamp":1774269086,"startTime":"0","endTime":"0","summary":"TP-03（洛替拉纳滴眼液）0.25%浓度制剂已正式获得中国监管机构批准，用于蠕形螨睑缘炎的治疗方案。此次获批将激活一项重大财务条款，Tarsus Pharmaceuticals, Inc.因此可获得1500万美元的里程碑付款。\n该药物作为专门针对眼部蠕形螨感染的靶向疗法，其获批标志着中国眼科治疗领域的重要进展。里程碑付款的触发也反映出合作方对TP-03市场潜力的认可。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TARS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618021209","title":"Tarsus Pharmaceuticals, Inc.盘中异动 急速下挫5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618021209","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2618021209?lang=zh_cn&edition=full","pubTime":"2026-03-11 22:07","pubTimestamp":1773238048,"startTime":"0","endTime":"0","summary":"北京时间2026年03月11日22时07分，Tarsus Pharmaceuticals, Inc.股票出现波动，股价快速下跌5.00%。Tarsus Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为0.45%。其相关个股中，Kala Bio, Inc.、Acurx Pharmaceuticals, Inc.、Ocugen, Inc.涨幅较大，60 Degrees Pharmaceuticals, Inc.、Acurx Pharmaceuticals, Inc.、Quince Therapeutics, Inc.较为活跃，换手率分别为954.13%、540.04%、44.28%，振幅较大的相关个股有Kala Bio, Inc.、Acurx Pharmaceuticals, Inc.、Tevogen Bio Holdings Inc C/Wts 14/02/2029 ，振幅分别为35.05%、34.13%、24.63%。Tarsus Pharmaceuticals, Inc.公司简介：Tarsus Pharmaceuticals Inc 是一家处于商业化阶段的生物制药公司，从眼部护理开始，专注于开发和商业化治疗药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026031122072997add5f1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026031122072997add5f1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","TARS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177007988","title":"Tarsus制药任命生物制药界翘楚、艾尔建前CEO David Pyott加入董事会","url":"https://stock-news.laohu8.com/highlight/detail?id=1177007988","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1177007988?lang=zh_cn&edition=full","pubTime":"2026-02-18 21:31","pubTimestamp":1771421477,"startTime":"0","endTime":"0","summary":"生物制药企业Tarsus Pharmaceuticals, Inc.宣布重磅人事变动，邀请业界权威人物David Pyott加入其董事会。Pyott先生曾担任知名药企艾尔建（Allergan）的首席执行官，在生物制药领域拥有深厚的管理经验和行业影响力。\n此次任命将为Tarsus制药带来宝贵的战略视野和行业资源。Pyott在医药行业的卓越领导力与Tarsus的创新药物研发方向高度契合，预计将助力公司加速推进产品管线布局和市场拓展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TARS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518278443","title":"Tarsus Pharmaceuticals, Inc.盘中异动 早盘大幅下挫5.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518278443","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518278443?lang=zh_cn&edition=full","pubTime":"2025-03-10 22:01","pubTimestamp":1741615315,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日22时01分，Tarsus Pharmaceuticals, Inc.股票出现波动，股价急速下挫5.19%。Tarsus Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.12%。其相关个股中，Checkpoint Therapeutics, Inc.、Trevi Therapeutics, Inc.、Mineralys Therapeutics, Inc.涨幅较大，Scisparc Ltd.、Dogwood Therapeutics, Inc.、Aeon Biopharma, Inc.较为活跃，换手率分别为666.08%、322.06%、92.32%，振幅较大的相关个股有Dogwood Therapeutics, Inc.、Scisparc Ltd.、Impact Biomedical, Inc.，振幅分别为41.36%、40.24%、28.59%。Tarsus Pharmaceuticals, Inc.公司简介：Tarsus Pharmaceuticals Inc是一家商业阶段的生物制药公司，从眼部护理开始，专注于治疗药物的开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031022015598a2a50d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031022015598a2a50d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["TARS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517114703","title":"杰富瑞投资银行：维持Tarsus Pharmaceuticals(TARS.US)评级，由买入调整至买入评级, 目标价由54.00美元调整至58.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2517114703","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517114703?lang=zh_cn&edition=full","pubTime":"2025-03-07 07:02","pubTimestamp":1741302171,"startTime":"0","endTime":"0","summary":"杰富瑞投资银行：维持Tarsus Pharmaceuticals(TARS.US)评级，由买入调整至买入评级, 目标价由54.00美元调整至58.00美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/07070248578853.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["TARS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517600796","title":"Tarsus Pharmaceuticals, Inc.盘中异动 下午盘股价大涨5.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517600796","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517600796?lang=zh_cn&edition=full","pubTime":"2025-03-05 03:02","pubTimestamp":1741114942,"startTime":"0","endTime":"0","summary":"北京时间2025年03月05日03时02分，Tarsus Pharmaceuticals, Inc.股票出现异动，股价快速上涨5.08%。Tarsus Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.05%。Tarsus Pharmaceuticals, Inc.公司简介：Tarsus Pharmaceuticals Inc是一家商业阶段的生物制药公司，从眼部护理开始，专注于治疗药物的开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305030223963984dd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305030223963984dd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","TARS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516552737","title":"Tarsus Pharmaceuticals, Inc.2024财年实现净利润-1.16亿美元，同比增加14.71%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516552737","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516552737?lang=zh_cn&edition=full","pubTime":"2025-03-02 00:00","pubTimestamp":1740844851,"startTime":"0","endTime":"0","summary":"3月2日，Tarsus Pharmaceuticals, Inc.公布财报，公告显示公司2024财年净利润为-1.16亿美元，同比增加14.71%；其中营业收入为1.83亿美元，同比增加948.71%，每股基本收益为-3.07美元。机构评级：截至2025年3月2日，当前有9家机构对Tarsus Pharmaceuticals, Inc.目标价做出预测，其中目标均价为67.33美元，其中最低目标价为45.00美元，最高目标价为85.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250302000104abe2c56e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250302000104abe2c56e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["TARS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514685738","title":"Guggenheim：维持Tarsus Pharmaceuticals(TARS.US)评级，由买入调整至买入评级, 目标价由75.00美元调整至78.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2514685738","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514685738?lang=zh_cn&edition=full","pubTime":"2025-02-27 00:11","pubTimestamp":1740586273,"startTime":"0","endTime":"0","summary":"Guggenheim：维持Tarsus Pharmaceuticals(TARS.US)评级，由买入调整至买入评级, 目标价由75.00美元调整至78.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/27001148413689.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["TARS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129601831","title":"异动解读 | Tarsus Pharmaceuticals盘中大涨5.74% 业绩良好成为主因","url":"https://stock-news.laohu8.com/highlight/detail?id=1129601831","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1129601831?lang=zh_cn&edition=full","pubTime":"2025-02-26 23:19","pubTimestamp":1740583169,"startTime":"0","endTime":"0","summary":"Tarsus Pharmaceuticals, Inc.(TARS)今日盘中股价大涨5.74%,引发了市场的广泛关注。\n\n从公司业绩来看,最新财报显示Tarsus实现营业收入1.83亿美元,毛利1.70亿美元,净亏损1.16亿美元,每股亏损3.07美元。尽管出现亏损,但营收和毛利都较为可观,表明公司主营业务发展顺利,有望在未来实现盈利。\n\n此外,89%的分析师给予该股买入评级,反映出外界对Tarsus未来前景的乐观预期。该公司旗舰产品XDEMVY是一种创新的治疗蠕形螨眼炎的眼药水,目前处于研究阶段,未来获批上市后有望带来新的利润增长点。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"异动解读 | Tarsus Pharmaceuticals盘中大涨5.74% 业绩良好成为主因","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["TARS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514562678","title":"Tarsus Pharmaceuticals, Inc.盘中异动 股价大涨5.96%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514562678","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514562678?lang=zh_cn&edition=full","pubTime":"2025-02-26 22:31","pubTimestamp":1740580305,"startTime":"0","endTime":"0","summary":"北京时间2025年02月26日22时31分，Tarsus Pharmaceuticals, Inc.股票出现异动，股价急速上涨5.96%。Tarsus Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.12%。其相关个股中，Enveric Biosciences, Inc.、Nutriband Inc C/Wts 、Channel Therapeutics Corporation涨幅较大，Enveric Biosciences, Inc.、Organovo Holdings, Inc.、Cns Pharmaceuticals, Inc.较为活跃，换手率分别为2740.08%、114.80%、89.53%，振幅较大的相关个股有Enveric Biosciences, Inc.、Cns Pharmaceuticals, Inc.、Channel Therapeutics Corporation，振幅分别为25.42%、14.35%、10.67%。Tarsus Pharmaceuticals, Inc.公司简介：Tarsus Pharmaceuticals Inc是一家商业阶段的生物制药公司，从眼部护理开始，专注于治疗药物的开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502262231459893aac6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502262231459893aac6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","TARS"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.tarsusrx.com","stockEarnings":[{"period":"1week","weight":0.0681},{"period":"1month","weight":0.2035},{"period":"3month","weight":0.1076},{"period":"6month","weight":0.1385},{"period":"1year","weight":0.2782},{"period":"ytd","weight":-0.1549}],"compareEarnings":[{"period":"1week","weight":0.004},{"period":"1month","weight":0.0285},{"period":"3month","weight":0.0503},{"period":"6month","weight":0.1387},{"period":"1year","weight":0.2037},{"period":"ytd","weight":0.1385}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Tarsus Pharmaceuticals, Inc.是根据特拉华州法律于2016年11月成立的公司。该公司是一家处于临床后期的生物制药公司，致力于治疗性候选药物的开发和商业化，以解决最初存在眼科疾病的巨大市场机遇有限的治疗选择。该公司的主要产品候选产品TP-03是2b/3期的新型疗法，目前正在开发中，用于治疗由蠕形螨引起的眼睑炎，这被称为蠕形螨眼。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.002743},{"month":2,"riseRate":0.333333,"avgChangeRate":0.037237},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.051747},{"month":4,"riseRate":0.5,"avgChangeRate":0.00177},{"month":5,"riseRate":0.5,"avgChangeRate":-0.038644},{"month":6,"riseRate":0.5,"avgChangeRate":-0.027034},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.030731},{"month":8,"riseRate":0.833333,"avgChangeRate":0.131807},{"month":9,"riseRate":0.8,"avgChangeRate":0.033781},{"month":10,"riseRate":0.8,"avgChangeRate":0.135195},{"month":11,"riseRate":0.666667,"avgChangeRate":0.092511},{"month":12,"riseRate":0.666667,"avgChangeRate":0.122111}],"exchange":"NASDAQ","name":"Tarsus Pharmaceuticals, Inc.","nameEN":"Tarsus Pharmaceuticals, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Tarsus Pharmaceuticals, Inc.(TARS)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Tarsus Pharmaceuticals, Inc.(TARS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Tarsus Pharmaceuticals, Inc.,TARS,Tarsus Pharmaceuticals, Inc.股票,Tarsus Pharmaceuticals, Inc.股票老虎,Tarsus Pharmaceuticals, Inc.股票老虎国际,Tarsus Pharmaceuticals, Inc.行情,Tarsus Pharmaceuticals, Inc.股票行情,Tarsus Pharmaceuticals, Inc.股价,Tarsus Pharmaceuticals, Inc.股市,Tarsus Pharmaceuticals, Inc.股票价格,Tarsus Pharmaceuticals, Inc.股票交易,Tarsus Pharmaceuticals, Inc.股票购买,Tarsus Pharmaceuticals, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Tarsus Pharmaceuticals, Inc.(TARS)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Tarsus Pharmaceuticals, Inc.(TARS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}